Document is current
Any future updates will be listed below
-
Authors
Abikenari, Matthew
Regev, Amit
Himic, Vratko
Choi, John
Jeyaretna, Sanjeeva
Fountain, Daniel M.
Lim, Michael
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 12 May 2025
First Online: 20 May 2025
Declarations
:
: Michael Lim (Funding from Arbor Pharmaceuticals, Accuray, BMS, Novartis; Consultant: BMS, Merck, SQZ Biotechnologies, Tocagen, VBI; Patents: Combining Focused Radiation and Immunotherapy, Combining Local Chemotherapy and Immunotherapy; Shareholder: Egret Therapeutics). Michael Lim is also a member of the editorial board for the current Journal (JNO). All other authors have no conflict to declare.
